AU4096100A - Pseudotyped retroviral vector for gene therapy of cancer - Google Patents

Pseudotyped retroviral vector for gene therapy of cancer

Info

Publication number
AU4096100A
AU4096100A AU40961/00A AU4096100A AU4096100A AU 4096100 A AU4096100 A AU 4096100A AU 40961/00 A AU40961/00 A AU 40961/00A AU 4096100 A AU4096100 A AU 4096100A AU 4096100 A AU4096100 A AU 4096100A
Authority
AU
Australia
Prior art keywords
cancer
gene therapy
retroviral vector
pseudotyped retroviral
pseudotyped
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU40961/00A
Other languages
English (en)
Inventor
Jacques Galipeau
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CENTRE FOR TRANSLATIONAL RESEARCH IN CANCER
Original Assignee
CT FOR TRANSLATIONAL RES IN CA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CT FOR TRANSLATIONAL RES IN CA filed Critical CT FOR TRANSLATIONAL RES IN CA
Publication of AU4096100A publication Critical patent/AU4096100A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13061—Methods of inactivation or attenuation
    • C12N2740/13062—Methods of inactivation or attenuation by genetic engineering
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU40961/00A 1999-04-23 2000-04-20 Pseudotyped retroviral vector for gene therapy of cancer Abandoned AU4096100A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13068099P 1999-04-23 1999-04-23
US60130680 1999-04-23
PCT/CA2000/000445 WO2000065034A2 (fr) 1999-04-23 2000-04-20 Pseudotype de vecteur retroviral destine a la therapie genique du cancer

Publications (1)

Publication Number Publication Date
AU4096100A true AU4096100A (en) 2000-11-10

Family

ID=22445832

Family Applications (1)

Application Number Title Priority Date Filing Date
AU40961/00A Abandoned AU4096100A (en) 1999-04-23 2000-04-20 Pseudotyped retroviral vector for gene therapy of cancer

Country Status (4)

Country Link
EP (1) EP1173551A2 (fr)
AU (1) AU4096100A (fr)
CA (1) CA2371216A1 (fr)
WO (1) WO2000065034A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002074941A1 (fr) * 2001-03-21 2002-09-26 Ipf Pharmaceuticals Gmbh Virus rapporteur comportant des proteines d'enveloppe heterologues
KR100491299B1 (ko) * 2001-09-29 2005-05-24 학교법인연세대학교 개선된 질환 치료 효과를 갖는 재조합 아데노바이러스 및그를 포함하는 약제학적 조성물
US20050100890A1 (en) * 2003-10-15 2005-05-12 Davidson Beverly L. Methods for producing and using in vivo pseudotyped retroviruses
CN102978239A (zh) * 2012-12-12 2013-03-20 广西壮族自治区水产研究所 两个对虾新型表达载体构建方法
WO2020043765A1 (fr) * 2018-08-30 2020-03-05 Miltenyi Biotec Gmbh Lignée cellulaire d'encapsidation négative ldlr pour la production de particules de vecteur rétroviral pseudotypées vsv-g ou de particules virales correspondantes
BR112021013180A2 (pt) * 2019-01-06 2022-04-12 Abintus Bio Inc Composição farmacêutica, vetor viral não replicante, e, método para prover terapia celular adotiva
CN113717990B (zh) * 2021-08-30 2023-08-15 武汉大学 一种基于双报告基因的新型水泡性口炎假病毒系统及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5512421A (en) * 1991-02-19 1996-04-30 The Regents Of The University Of California Generation, concentration and efficient transfer of VSV-G pseudotyped retroviral vectors
US5952225A (en) * 1994-08-17 1999-09-14 Genetic Therapy, Inc. Retroviral vectors produced by producer cell lines resistant to lysis by human serum
US5750396A (en) * 1995-05-08 1998-05-12 St. Judes Children's Research Hospital Stable virus packaging cell lines
CA2296319A1 (fr) * 1997-07-18 1999-01-28 Chiron Corporation Vecteurs lentiviraux

Also Published As

Publication number Publication date
WO2000065034A3 (fr) 2001-01-25
WO2000065034A2 (fr) 2000-11-02
CA2371216A1 (fr) 2000-11-02
EP1173551A2 (fr) 2002-01-23

Similar Documents

Publication Publication Date Title
AU4563300A (en) Regulation of viral gene expression
AU3737297A (en) Bacteriophage-mediated gene therapy
AU3009801A (en) Combinations of medicaments for treating viral diseases
EP1176964B8 (fr) Utilisation du compose et743 pour le traitement du cancer
AU3169495A (en) Gene therapy for restenosis using an adenoviral vector
AU4770297A (en) Receptor-mediated gene transfer system for targeting tumor gene therapy
AU4096100A (en) Pseudotyped retroviral vector for gene therapy of cancer
AU4401297A (en) Improved retroviral vectors for gene therapy
HUP0104046A3 (en) Adenovirus-mediated gene therapy
AU3082401A (en) Therapy of psoriasis
AU1916601A (en) Oncolytic combinations for the treatment of cancer
AU6085500A (en) A lung cancer associated retrovirus, gene delivery vector and methods of use thereof
AU4369800A (en) Treatment of metastatic cancer through mts-1 gene
AU1916501A (en) Oncolytic combinations for the treatment of cancer
AU2002347813A1 (en) Chimeric viral vectors for gene therapy
AU1917101A (en) Oncolytic combinations for the treatment of cancer
AU1595001A (en) Oncolytic combinations for the treatment of cancer
AU7544098A (en) Somatic gene therapy to suppress secondary cataract formation
AU1595101A (en) Oncolytic combinations for the treatment of cancer
AU5552400A (en) Treatment of cancer
AUPQ367699A0 (en) Treatment of cancer
AU2002316788A1 (en) Retroviral vectors for gene therapy
AU5778399A (en) Gene therapy for treatment of cancer
AU7920198A (en) Intratumoral administration of triphenylethylenes for the treatment of cancer
GB9924981D0 (en) Gene therapy

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase